Cardiology

Vioxx photo illo
Pharma

The return of Vioxx: Can a drug once deemed deadly be relaunched to treat rare disease?

By Damian Garde

Heart ultrasound GIF
Health

An AI startup, led by 23andMe veteran Andy Page, tries to take better pictures of the heart

By Matthew Herper

Pharmalot

Sandoz halts global distribution of heartburn med over carcinogen link while Canada tells other manufacturers to stop

By Ed Silverman

FDA campus
Pharmalot

FDA and EMA are now probing carcinogen in Zantac and other heartburn meds

By Ed Silverman

Sept 11 Firefighters Health
Health

Some 9/11 firefighters may have higher heart risks now

By Associated Press

Regeneron
Biotech

Regeneron drug proves effective in genetic form of high cholesterol

By Matthew Herper and Damian Garde

Vascepa pill handout
Biotech

Amarin now says FDA plans outside panel review of its Vascepa heart drug, delaying approval decision

By Adam Feuerstein

AI and heart disease
Health Tech

5 ways artificial intelligence is already changing cardiac care

By Casey Ross

Health

Study: Millions should stop using aspirin for heart health

By Associated Press

In the Lab

A family’s medical mystery sheds light on the surprising ways disease-causing genes can be inherited

By Andrew Joseph

Heart & BP monitor
In the Lab

Attempt to replicate clinical trials with real-world data generates real-world criticism, too

By Matthew Herper

Vascepa pill handout
Business

Amarin raises sales guidance for heart drug Vascepa, hires more sales reps for larger marketing push

By Adam Feuerstein

Emergency dialing 911
First Opinion

In a medical emergency, who in your social network will call for help quickest?

By Amar Dhand

Long shadow of Alexa
In the Lab

‘Alexa, are you listening?’ An experimental tool warns of cardiac arrest by monitoring breathing

By Diana Cai

Blood pressure check
Health

Patients whose blood pressure only spikes at the doctor’s office are twice as likely to die of a heart attack or other cardiac event

By Ruth Hailu

Football 1961
Health

Former NFL players die at a faster rate than other professional athletes, study finds

By Shraddha Chakradhar

Adam's Take

Fibrogen’s obtuse disclosures about anemia pill raise concerns over heart safety, putting approval at risk

By Adam Feuerstein

Play
The Readout LOUD

Listen: Pharma felonies, cardiac CRISPR, and a strange day at the FDA

By Damian Garde and Adam Feuerstein

Sekar Kathiresan, Verve CEO
Biotech

With a superstar cardiologist as its CEO, new CRISPR company targets heart disease

By Sharon Begley

Current device
Health

A machine learning device, meant to monitor the chronically ill, moves into homes

By Casey Ross

High Blood Pressure
Health

For its next phase, the Framingham Heart Study will explore the biology of aging

By Robert Weisman — Boston Globe

Peter Bucciarelli
Health

Hepatitis C-infected hearts and lungs can be safely transplanted, study says, opening way to more donors

By Jacquelyn Corley

Lipitor
First Opinion

Preventing heart disease requires more than medicine

By Robert M. Kaplan

Amarin Transcript
Hospitals

CMS proposes changing requirements for less-invasive heart valve procedure

By Matthew Herper

Easier Heart Valves
Business

The astounding 19-year journey to a sea change for heart patients

By Matthew Herper

Vascepa pill handout
Health

Amarin’s Vascepa prevents second and third heart attacks in analysis, fueling debate

By Matthew Herper

Clogged Artery
Biotech

New results show benefits of Esperion’s cholesterol drug — but leave big questions unanswered

By Matthew Herper

Red blood cells
Biotech

Tiny PhaseBio gets the New England Journal’s spotlight. Can its shares rebound?

By Matthew Herper

Health

Next for Apple Watch: a ‘pragmatic’ clinical trial with J&J to track heart health

By Matthew Herper

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy